PMID- 31892574
OWN - NLM
STAT- MEDLINE
DCOM- 20200110
LR  - 20200110
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 40
IP  - 1
DP  - 2020 Jan
TI  - The Rectus Sheath Block (RSB) Analgesia Following Laparotomy Could Affect 
      Malonidialdehyde (MDA) Concentrations in Benign Disease and Cancer.
PG  - 253-259
LID - 10.21873/anticanres.13947 [doi]
AB  - BACKGROUND/AIM: The aim of the study was to compare the MDA (malonidialdehyde) 
      plasma concentrations versus CAT (catalase)/NT (nitrotyrosine) plasma 
      concentrations, patient satisfaction and pain score at rest/pressure to the wound 
      area in laparotomy patients with rectus sheath block (RSB) analgesia. PATIENTS 
      AND METHODS: Initially, 56 patients were randomized to four groups; control group 
      (n=12), single-dose (n=16), repeated-dose (n=12) and continuous infusion (n=16) 
      RSB analgesia groups. The plasma concentrations of CAT, NT and MDA markers were 
      measured just before, immediately after and 24 h after operation. RESULTS: The 
      RSB analgesia enhanced significantly patient satisfaction (p=0.001). The plasma 
      MDA decreased immediately after operation (POP1) and the postoperative decrease 
      between the preoperative and the POP1 values in the MDA marker were statistically 
      significant (p<0.001). In linear mixed model, the time effect in both the single 
      group and in the benign group in plasma NT biomarker was statistically 
      significant (p=0.001, p=0.013, respectively). The median plasma MDA 
      concentrations (ng/ml) following surgery were significantly lower in patients 
      with cancer versus patients with benign disease (589 vs. 852, p=0.021). 
      Jitterplots of the individual plasma NT versus plasma MDA showed that there was 
      significant correlation in benign and cancer patients (r=0.347, p<0.001). 
      CONCLUSION: Plasma MDA decreased significantly after operation in all patients 
      and cancer patients had significantly lower MDA concentrations following surgery 
      than patients with benign disease.
CI  - Copyright(c) 2020, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Ruottinen, Maiju
AU  - Ruottinen M
AD  - Department of Surgery, Kuopio University Hospital and School of Medicine, 
      University of Eastern Finland, Kuopio, Finland.
FAU - Kuosmanen, Viivi
AU  - Kuosmanen V
AD  - Department of Surgery, Kuopio University Hospital and School of Medicine, 
      University of Eastern Finland, Kuopio, Finland.
FAU - Saimanen, Iina
AU  - Saimanen I
AD  - Department of Surgery, Kuopio University Hospital and School of Medicine, 
      University of Eastern Finland, Kuopio, Finland.
FAU - Kaaronen, Viivi
AU  - Kaaronen V
AD  - Department of Surgery, Kuopio University Hospital and School of Medicine, 
      University of Eastern Finland, Kuopio, Finland.
FAU - Rahkola, Dina
AU  - Rahkola D
AD  - Department of Surgery, Kuopio University Hospital and School of Medicine, 
      University of Eastern Finland, Kuopio, Finland.
FAU - Holopainen, Anu
AU  - Holopainen A
AD  - Department of Clinical Chemistry, Eastern Finland Laboratory Center, Kuopio 
      University Hospital, Kuopio, Finland.
FAU - Selander, Tuomas
AU  - Selander T
AD  - Science Service Center, Kuopio University Hospital, Kuopio, Finland.
FAU - Kokki, Hannu
AU  - Kokki H
AD  - Department of Anaesthesiology and Intensive Care, Kuopio University Hospital and 
      School of Medicine, University of Eastern Finland, Kuopio, Finland.
FAU - Kokki, Merja
AU  - Kokki M
AD  - Department of Anaesthesiology and Intensive Care, Kuopio University Hospital and 
      School of Medicine, University of Eastern Finland, Kuopio, Finland.
FAU - Eskelinen, Matti
AU  - Eskelinen M
AD  - Department of Surgery, Kuopio University Hospital and School of Medicine, 
      University of Eastern Finland, Kuopio, Finland matti.eskelinen@kuh.fi.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 3604-79-3 (3-nitrotyrosine)
RN  - 42HK56048U (Tyrosine)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - EC 1.11.1.6 (Catalase)
SB  - IM
MH  - *Analgesia
MH  - Catalase/blood
MH  - Female
MH  - Humans
MH  - *Laparotomy
MH  - Male
MH  - Malondialdehyde/*blood
MH  - Middle Aged
MH  - Neoplasms/*blood
MH  - *Nerve Block
MH  - Tyrosine/analogs & derivatives/blood
OTO - NOTNLM
OT  - Benign disease
OT  - cancer
OT  - lipid peroxidation
OT  - pain following surgery
OT  - plasma malonidialdehyde
EDAT- 2020/01/02 06:00
MHDA- 2020/01/11 06:00
CRDT- 2020/01/02 06:00
PHST- 2019/12/02 00:00 [received]
PHST- 2019/12/10 00:00 [revised]
PHST- 2019/12/12 00:00 [accepted]
PHST- 2020/01/02 06:00 [entrez]
PHST- 2020/01/02 06:00 [pubmed]
PHST- 2020/01/11 06:00 [medline]
AID - 40/1/253 [pii]
AID - 10.21873/anticanres.13947 [doi]
PST - ppublish
SO  - Anticancer Res. 2020 Jan;40(1):253-259. doi: 10.21873/anticanres.13947.